DYN — Dyne Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1818794 ·
Last close
$25.99
Market Cap
$4.85B
52W High
$27.31
52W Low
$16.56
ADV30
2,344,860
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -181,661,000 | -178,556,000 | 994,013,000 | 676,114,000 | 291,862,000 |
| Mar 2026 | 0 | — | -125,276,000 | -120,854,000 | 1,079,950,000 | 753,102,000 | 214,895,000 |
| Dec 2025 | 0 | — | -116,129,000 | -111,955,000 | 1,186,958,000 | 893,369,000 | 214,829,000 |
| Sep 2025 | 0 | — | -113,892,000 | -108,041,000 | 867,059,000 | 573,610,000 | 175,276,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-477,819,000
Investing CF
$-44,170,000
Financing CF
$713,466,000
CapEx
$-21,404,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.33
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,695,552,000
Inventory
—
Receivables
—
ST Investments
$222,361,000
EBIT TTM
$-504,511,000
Pretax Income TTM
$-519,406,000
Interest Exp TTM
$14,895,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -468,184,000 | -446,214,000 | 1,186,958,000 | 214,829,000 | — | -403,207,000 |
| Dec 2024 | 0 | -343,886,000 | -317,418,000 | 691,234,000 | 61,396,000 | — | -292,369,000 |
| Dec 2023 | 0 | -242,162,000 | -235,937,000 | 165,082,000 | 73,790,000 | — | -188,158,000 |
| Dec 2022 | 0 | -170,962,000 | -168,099,000 | 306,325,000 | 53,961,000 | — | -153,645,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.34
Max Pain — expiry 2026-12-18
max pain strike: $25.00 · spot: $26.25 · call oi: 1,115 · put oi: 4,593Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | $4.86B | $44.72 | — |
| GIFLF | Grifols SA | $4.97B | $11.76 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $5.08B | $29.65 | — |
| ELVN | Enliven Therapeutics, Inc. | $4.48B | $61.15 | — |
| GIKLY | Grifols SA | $4.31B | $5.10 | — |
News headlines (Yahoo Finance, 1h cache)
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?
2026-07-23 11:08 · Yahoo
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)
2026-07-22 12:29 · Yahoo
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
2026-07-22 02:46 · Yahoo
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock
2026-07-22 00:06 · Yahoo
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space
2026-07-21 20:04 · Yahoo
Sarepta Skids After A Rival Clears A Key Hurdle In The Duchenne Space
2026-07-20 20:28 · Yahoo
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
2026-07-20 11:30 · Yahoo
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
2026-07-04 13:41 · Yahoo
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
2026-07-01 15:58 · Yahoo
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
2026-07-21 14:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.